XORTX Therapeutics Inc.
3710 – 33rd Street NW
Alberta Beach, AB T2L 2M1
Canada
(403) 455-7727
https://www.xortx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 2
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Allen Warren Davidoff Ph.D. | Founder, CEO, President & Director | 337.79k | 無 | 1960 |
| Mr. James Neville Fairbairn C.A., C.P.A., ICD.D | Chief Financial Officer | 76.2k | 無 | 1963 |
| Dr. Stephen Haworth M.D., MRCP | Chief Medical Officer | 200.23k | 無 | 1950 |
| Dr. Stacy Evans M.B.A., M.D. | Chief Business Officer | 280k | 無 | 1974 |
| Nick Rigopoulos | Director of Communications | 無 | 無 | 無 |
| Dr. David Sans M.B.A., Ph.D. | Director of Corporate Development | 無 | 無 | 1970 |
| Dr. David MacDonald Ph.D. | Consultant of Clinical Operations | 無 | 無 | 1964 |
| Ms. Charlotte May | Corporate Secretary | 無 | 無 | 無 |
描述
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
公司管治
截至 無 止，XORTX Therapeutics Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
